Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Phase I clinical studies with cytotoxic drugs: pharmacokinetic and pharmacodynamic considerations.

Literature DB >> 2178663

Phase I clinical studies with cytotoxic drugs: pharmacokinetic and pharmacodynamic considerations.

D R Newell¹.

Abstract

Mesh：

Substances：
Antineoplastic Agents

Year: 1990 PMID： 2178663 PMCID： PMC1971416 DOI： 10.1038/bjc.1990.35

Source DB: PubMed Journal: Br J Cancer ISSN： 0007-0920 Impact factor: 7.640

× No keyword cloud information.

9 in total

1. Quantitative comparison of toxicity of anticancer agents in mouse, rat, hamster, dog, monkey, and man.

Authors: E J Freireich; E A Gehan; D P Rall; L H Schmidt; H E Skipper
Journal: Cancer Chemother Rep Date: 1966-05

2. Comparative pharmacokinetics of cisplatin and three analogues in mice and humans.

Authors: M B van Hennik; W J van der Vijgh; I Klein; F Elferink; J B Vermorken; B Winograd; H M Pinedo
Journal: Cancer Res Date: 1987-12-01 Impact factor: 12.701

3. Pharmacokinetics and dosage reduction of cis-diammine(1,1-cyclobutanedicarboxylato)platinum in patients with impaired renal function.

Authors: M J Egorin; D A Van Echo; S J Tipping; E A Olman; M Y Whitacre; B W Thompson; J Aisner
Journal: Cancer Res Date: 1984-11 Impact factor: 12.701

4. Quantitative prediction of drug toxicity in humans from toxicology in small and large animals.

Authors: M A Goldsmith; M Slavik; S K Carter
Journal: Cancer Res Date: 1975-05 Impact factor: 12.701

5. Therapeutic response in phase I trials of antineoplastic agents.

Authors: E Estey; D Hoth; R Simon; S Marsoni; B Leyland-Jones; R Wittes
Journal: Cancer Treat Rep Date: 1986-09

6. Relation of preclinical toxicology to findings in early clinical trials.

Authors: C K Grieshaber; S Marsoni
Journal: Cancer Treat Rep Date: 1986-01

7. Preclinical pharmacology of the anthrapyrazole analog oxantrazole (NSC-349174, piroxantrone).

Authors: S K Frank; D A Mathiesen; M Szurszewski; M J Kuffel; M M Ames
Journal: Cancer Chemother Pharmacol Date: 1989 Impact factor: 3.333

8. The role of comparative pharmacokinetics in the planning of human dose escalation: the experience with diacetyldianhydrogalactitol.

Authors: S Kerpel-Fronius; V Erdélyi-Tóth; S Somfai-Relle; J Csetényi; P Kovács; G Ujj; B Kanyár
Journal: Cancer Chemother Pharmacol Date: 1988 Impact factor: 3.333

9. A phase I and pharmacokinetic study of amphethinile.

Authors: D B Smith; C Ewen; J Mackintosh; B W Fox; N Thatcher; J H Scarffe; R Vezin; D Crowther
Journal: Br J Cancer Date: 1988-06 Impact factor: 7.640

9 in total

6 in total

Review 1. Concentration-controlled trials. What does the future hold?

Authors: A Johnston; D W Holt
Journal: Clin Pharmacokinet Date: 1995-02 Impact factor: 6.447

Review 2. Normalisation of anti-cancer drug dosage using body weight and surface area: is it worthwhile? A review of theoretical and practical considerations.

Authors: J J Reilly; P Workman
Journal: Cancer Chemother Pharmacol Date: 1993 Impact factor: 3.333

3. Dose response evaluation. Use of plasma concentration confidence intervals as a tool to predict optimal drug dose ratio.

Authors: P E Lønning
Journal: Clin Pharmacokinet Date: 1993-07 Impact factor: 6.447